{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,24]],"date-time":"2026-04-24T08:02:24Z","timestamp":1777017744581,"version":"3.51.4"},"reference-count":19,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2017,10,1]],"date-time":"2017-10-01T00:00:00Z","timestamp":1506816000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","diabet-metabolism.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Diabetes & Metabolism"],"published-print":{"date-parts":[[2017,10]]},"DOI":"10.1016\/j.diabet.2017.03.001","type":"journal-article","created":{"date-parts":[[2017,4,20]],"date-time":"2017-04-20T02:47:33Z","timestamp":1492656453000},"page":"446-452","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":26,"title":["Glycaemic control and hypoglycaemia with insulin glargine 300 U\/mL compared with glargine 100 U\/mL in Japanese adults with type 2 diabetes using basal insulin plus oral anti-hyperglycaemic drugs (EDITION JP 2 randomised 12-month trial including 6-month extension)"],"prefix":"10.1016","volume":"43","author":[{"given":"Y.","family":"Terauchi","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M.","family":"Koyama","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"X.","family":"Cheng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M.","family":"Sumi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M.C.","family":"Riddle","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"G.B.","family":"Bolli","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"T.","family":"Hirose","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.diabet.2017.03.001_bib0100","series-title":"IDF Diabetes Atlas","author":"International Diabetes Federation","year":"2015"},{"key":"10.1016\/j.diabet.2017.03.001_bib0105","doi-asserted-by":"crossref","first-page":"2129","DOI":"10.1001\/jama.2009.726","article-title":"Diabetes in Asia: epidemiology, risk factors, and pathophysiology","volume":"301","author":"Chan","year":"2009","journal-title":"J Am Med Assoc"},{"key":"10.1016\/j.diabet.2017.03.001_bib0110","first-page":"801","article-title":"Initiation of insulin for type 2 diabetes mellitus patients: what are the issues? A qualitative study","volume":"52","author":"Tan","year":"2011","journal-title":"Singapore Med J"},{"key":"10.1016\/j.diabet.2017.03.001_bib0115","doi-asserted-by":"crossref","first-page":"637","DOI":"10.2337\/dc14-0006","article-title":"New insulin glargine 300 Units. mL-1 provides a more even activity profile and prolonged glycemic control at steady state compared with insulin glargine 100 Units. mL-1","volume":"38","author":"Becker","year":"2015","journal-title":"Diabetes Care"},{"key":"10.1016\/j.diabet.2017.03.001_bib0120","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1111\/dom.12416","article-title":"Low within- and between-day variability in exposure to new insulin glargine 300 U\/ml","volume":"17","author":"Becker","year":"2015","journal-title":"Diabetes Obes Metab"},{"key":"10.1016\/j.diabet.2017.03.001_bib0125","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1111\/dom.12415","article-title":"Single-dose new insulin glargine 300 U\/ml provides prolonged, stable glycaemic control in Japanese and European people with type 1 diabetes","volume":"17","author":"Shiramoto","year":"2015","journal-title":"Diabetes Obes Metab"},{"key":"10.1016\/j.diabet.2017.03.001_bib0130","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1089\/dia.2015.0290","article-title":"Efficacy and safety of flexible versus fixed dosing intervals of insulin glargine 300 U\/mL in people with type 2 diabetes","volume":"18","author":"Riddle","year":"2016","journal-title":"Diabetes Technol Ther"},{"key":"10.1016\/j.diabet.2017.03.001_bib0135","doi-asserted-by":"crossref","first-page":"386","DOI":"10.1111\/dom.12438","article-title":"New insulin glargine 300 U\/mL compared with glargine 100 U\/mL in insulin-na\u00efve people with type 2 diabetes on oral glucose-lowering drugs: a randomized controlled trial (EDITION 3)","volume":"17","author":"Bolli","year":"2015","journal-title":"Diabetes Obes Metab"},{"key":"10.1016\/j.diabet.2017.03.001_bib0140","doi-asserted-by":"crossref","first-page":"2217","DOI":"10.2337\/dc15-0249","article-title":"New insulin glargine 300 Units\/mL versus glargine 100 units\/mL in people with type 1 diabetes: a randomized, phase 3a, open-label clinical trial (EDITION 4)","volume":"38","author":"Home","year":"2015","journal-title":"Diabetes Care"},{"key":"10.1016\/j.diabet.2017.03.001_bib0145","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1111\/dom.12619","article-title":"New insulin glargine 300 U\/ml versus glargine 100 U\/ml in Japanese adults with type 1 diabetes using basal and mealtime insulin: glucose control and hypoglycaemia in a randomized controlled trial (EDITION JP 1)","volume":"18","author":"Matsuhisa","year":"2016","journal-title":"Diabetes Obes Metab"},{"key":"10.1016\/j.diabet.2017.03.001_bib0150","doi-asserted-by":"crossref","first-page":"2755","DOI":"10.2337\/dc14-0991","article-title":"New insulin glargine 300 U\/mL versus glargine 100 U\/mL in people with type 2 diabetes using basal and mealtime insulin: glucose and hypoglycemia in a 6-month randomized controlled trial (EDITION I)","volume":"37","author":"Riddle","year":"2014","journal-title":"Diabetes Care"},{"key":"10.1016\/j.diabet.2017.03.001_bib0155","doi-asserted-by":"crossref","first-page":"366","DOI":"10.1111\/dom.12618","article-title":"New insulin glargine 300 U\/ml versus glargine 100 U\/ml in Japanese people with type 2 diabetes using basal insulin and oral antihyperglycaemic drugs: glucose control and hypoglycaemia in a randomized controlled trial (EDITION JP 2)","volume":"18","author":"Terauchi","year":"2016","journal-title":"Diabetes Obes Metab"},{"key":"10.1016\/j.diabet.2017.03.001_bib0160","doi-asserted-by":"crossref","first-page":"3235","DOI":"10.2337\/dc14-0990","article-title":"New insulin glargine 300 U\/mL versus glargine 100 U\/mL in people with type 2 diabetes using oral agents and basal insulin: glucose control and hypoglycemia in a 6-month randomized controlled trial (EDITION 2)","volume":"37","author":"Yki-J\u00e4rvinen","year":"2014","journal-title":"Diabetes Care"},{"key":"10.1016\/j.diabet.2017.03.001_bib0165","doi-asserted-by":"crossref","first-page":"835","DOI":"10.1111\/dom.12472","article-title":"One-year sustained glycaemic control and less hypoglycaemia with new insulin glargine 300 U\/ml compared with 100 U\/ml in people with type 2 diabetes using basal plus meal-time insulin: the EDITION 1 12-month randomized trial, including 6-month extension","volume":"17","author":"Riddle","year":"2015","journal-title":"Diabetes Obes Metab"},{"key":"10.1016\/j.diabet.2017.03.001_bib0170","doi-asserted-by":"crossref","first-page":"1142","DOI":"10.1111\/dom.12532","volume":"17","author":"Yki-Jarvinen","year":"2015","journal-title":"Diabetes Obes Metab"},{"key":"10.1016\/j.diabet.2017.03.001_bib0175","first-page":"45","article-title":"ICH harmonized tripartite guideline: guideline for good clinical practice","volume":"47","year":"2001","journal-title":"J Postgrad Med"},{"key":"10.1016\/j.diabet.2017.03.001_bib0180","series-title":"Declaration of Helsinki - Ethical principles for medical research involving human subjects","author":"World Medical Association","year":"2013"},{"key":"10.1016\/j.diabet.2017.03.001_bib0185","doi-asserted-by":"crossref","first-page":"1245","DOI":"10.2337\/diacare.28.5.1245","article-title":"Defining and reporting hypoglycemia in diabetes: a report from the American Diabetes Association Workgroup on Hypoglycemia","volume":"28","author":"ADA Workgroup on Hypoglycemia","year":"2005","journal-title":"Diabetes Care"},{"key":"10.1016\/j.diabet.2017.03.001_bib0190","doi-asserted-by":"crossref","first-page":"622","DOI":"10.1111\/dom.12072","article-title":"Clinical predictors of risk of hypoglycaemia during addition and titration of insulin glargine for type 2 diabetes mellitus","volume":"15","author":"Karl","year":"2013","journal-title":"Diabetes Obes Metab"}],"container-title":["Diabetes & Metabolism"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1262363617300496?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1262363617300496?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2022,7,27]],"date-time":"2022-07-27T17:54:34Z","timestamp":1658944474000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1262363617300496"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,10]]},"references-count":19,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2017,10]]}},"alternative-id":["S1262363617300496"],"URL":"https:\/\/doi.org\/10.1016\/j.diabet.2017.03.001","relation":{},"ISSN":["1262-3636"],"issn-type":[{"value":"1262-3636","type":"print"}],"subject":[],"published":{"date-parts":[[2017,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Glycaemic control and hypoglycaemia with insulin glargine 300 U\/mL compared with glargine 100 U\/mL in Japanese adults with type 2 diabetes using basal insulin plus oral anti-hyperglycaemic drugs (EDITION JP 2 randomised 12-month trial including 6-month extension)","name":"articletitle","label":"Article Title"},{"value":"Diabetes & Metabolism","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.diabet.2017.03.001","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2017 Elsevier Masson SAS. All rights reserved.","name":"copyright","label":"Copyright"}]}}